首页 | 官方网站   微博 | 高级检索  
     


Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study
Authors:Avivit Cahn MD  Itamar Raz MD  Marc Bonaca MD  Ofri Mosenzon MD  Sabina A. Murphy MPH  Ilan Yanuv MSc  Aliza Rozenberg MA  John P. H. Wilding MD  Deepak L. Bhatt MD  Darren K. McGuire MD  Ingrid A. M. Gause-Nilsson MD  Martin Fredriksson MD  Peter A. Johansson MSc  Gyorgy Jermendy MD  Samy Hadjadj MD  Anna Maria Langkilde MD  Marc S. Sabatine MD  Stephen D. Wiviott MD  Lawrence A. Leiter MD
Affiliation:1. Diabetes Unit, Department of Endocinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel;2. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts;3. Institute of Ageing and Chronic Disease, Faculty of Health and Life Science, University of Liverpool, Liverpool, UK;4. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Centre, Dallas, Texas;5. BioPharmaceuticals R&D, Gothenburg, Sweden;6. 3rd Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary;7. L'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Department of Endocrinology, Diabetes and Nutrition, Nantes, France;8. Li Ka Shing Knowledge Institute, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Canada
Abstract:
Keywords:acute kidney injury  dapagliflozin  diabetic ketoacidosis  fractures  genital infections  hypoglycemia  malignancy  safety  SGLT2 inhibitor  urinary tract infections  volume depletion
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号